Methylthioadenosine phosphorylase and activated insulin-like growth actor-1 receptor/insulin receptor: Potential therapeutic targets in chordoma

Journal of Pathology

Volumn 220, Issue 5, 2010, Pages 608-617

  Sommer, Josh ^a   Itani, Doha M ^b   Homlar, Kelly C ^c   Keedy, Vicki L ^d   Halpern, Jennifer L ^c   Holt, Ginger E ^c   Schwartz, Herbert S ^c   Coffin, Cheryl M ^b   Kelley, Michael J ^c   Cates, Justin M M ^b  

^a Chordoma Foundation   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BAD; CDKN2A; Chordoma; Immunohistochemistry; Insulin receptor; Insulinlike growth factor 1 receptor; Methylthioadenosine phosphorylase; Notochord; Sacrum; Skull base

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INSULIN RECEPTOR; PROTEIN BAD; SOMATOMEDIN C RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN NOTOCHORDAL CELL TUMOR; BENIGN TUMOR; CHILD; CHONDROSARCOMA; CHORDOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; METABOLISM; MOLECULAR DYNAMICS; NOTOCHORD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SCHOOL CHILD; SIGNAL TRANSDUCTION; SKELETAL CHONDROSARCOMA;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHONDROSARCOMA; CHORDOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NOTOCHORD; PHOSPHORYLATION; PROGNOSIS; PURINE-NUCLEOSIDE PHOSPHORYLASE; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77949845955     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2679     Document Type: Article

References (48)

1. Mirra J, Nelson S, Della Rocca C, Mertens F. Chordoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, Fletcher CD, Unni KK, Mertens F (eds). IARC Press: Lyon, 2002; 316-317.
2. Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003;10:291-296.
3. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11.
4. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999;175(Suppl 2):57-63.
5. Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, Mankin H, et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006;65:1514-1521.
6. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH, et al. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344-1350.
7. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol 2007;19:367-370.
8. Mitsuhashi T, Watanabe M, Sasano H, Ono M. The expression of insulin-like growth factor-1 (IGF-1), IGF-1 receptor and transforming growth factor-beta in chordoma. Mod Pathol 2006;19:6A.
9. Mitsuhashi T, Asanuma H, Hasegawa T. Insulin-like growth factor (IGF)-I and IGF-I receptor (IGF-IR) are consistently expressed in the most of chordomas. Mod Pathol 2008;21:15A-16A.
10. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008;20:419-427.
11. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
12. Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Invest Drugs 2008;17:1703-1715.
13. Chitnis MM, Yuen JSP, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14:6364-6370.
14. Hallor KH, Staaf J, Jönsson G, Heidenblad M, Vult von Steyern F, Bauer HCF, et al. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 2008;98:434-442.
15. García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, et al. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002;8:782-787.
16. Chow WA, Bedell V, Gaytan P, Borden E, Goldblum J, Hicks D, et al. Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas. Cancer Genet Cytogenet 2006;166:95-100.
17. Chen ZH, Zhang H, Savarese TM. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res 1996;56:1083-1090.
18. Hori H, Tran P, Carrera CJ, Hori Y, Rosenbach MD, Carson DA, et al. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 1996;56:5653-5658.
19. Fasig JH, Dupont WD, Olson SJ, LaFleur BJ, Cates JM. Steroid hormone receptor and COX-2 expression in chordoma. Am J Clin Pathol 2007;128:375-381.
20. R Development Core Team. R: a language and environment for statistical computing. http://www.R-project.org [4 July 2009].
21. Therneau T, Lumley L. Survival: survival analysis, including penalised likelihood. R package version 2.34-1. http://cran.rproject.org/web/packages/ survival/index.html [4 July 2009].
22. Horwitz T. The Human Notochord: A Study of its Development and Regression, Variations and Pathologic Derivative, Chordoma. Private printing: Horwitz, Indianapolis, 1977; 206.
23. Choi KS, Cohn MJ, Harfe BD. Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation. Dev Dyn 2008;237:3953-3958.
24. Yamaguchi T, Suzuki S, Ishiiwa H, Ueda Y. Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas? Histopathology 2004;44:597-602.
25. Yamaguchi T,Watanabe-Ishiiwa H, Suzuki S, Igarashi Y, Ueda Y. Incipient chordoma: a report of two cases of early-stage chordoma arising from benign notochordal cell tumors. Mod Pathol 2005;18:1005-1010.
26. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anticancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2002;2:191-207.
27. Fasig JH, Dupont WD, LaFleur BJ, Olson SJ, Cates JMM. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol 2008;34:95-104.
28. Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE, Ramesh V, et al. Aberrant hyperactivation of Akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 2009;15:1940-1946.
29. Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 2007;35:231-235.
30. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009;8:2502-2508.
31. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 1997;91:231-241.
32. Protein Modification Site. http://www.phosphosite.org/homeAction.do [2 September 2009].
33. Phospho.ELM Search. http://phospho.elm.eu.org/ [2 September 2009].
34. Park MJ, Kassam A, Gardner P, Prevedello DM, Soeda A, Lieberman F, et al. Platelet-derived growth factor stimulates chordoma growth and invasion by activating the PI3K/AKT/mTOR signaling pathway. Neuro Oncol 2008;10:764A.
35. Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 2009;100:1406-1414.
36. Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P, et al. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res 2009;29:1867-1871.
37. Al-Bazz Y, Underwood J, Brown B, Dobson P. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer 2009;45:694-704.
38. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
39. Berman H, Zhang J, Crawford YG, Gauthier ML, Fordyce CA, McDermott KM, et al. Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis. Cold Spring Harb Symp Quant Biol 2005;70:317-327.
40. McDermott KM, Zhang J, Holst CR, Kozakiewicz BK, Singla V, Tlsty TD, et al. p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol 2006;4:e51.
41. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PloS one 2009;4:e5735.
42. Takabatake Y, Takabatake T, Takeshima K. Conserved and divergent expression of T-box genes Tbx2-Tbx5 in Xenopus. Mech Dev 2000;91:433-437.
43. Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005;65:2260-2268.
44. Kindler HL, Burris HA, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs 2009;27:75-81.
45. Hirai H, Kawanishi N, Iwasawa Y. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Curr Top Med Chem 2005;5:167-179.
46. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006;5:2644-2658.
47. O'Reilly K, Rojo F, She Q, Solit D, Mills G, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
48. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009;20:1886-1894.